Cirrhosis with COVID‐19: Just another infection or something more to it?

The study specifically looked into the effect of COVID-19 in patients with compensated or decompensated cirrhosis (DC). [...]the study describes the readmission rate and causes of hospital readmission in cirrhotic patients with concomitant COVID-19. Another interesting observation was in patients who developed ACLF (NACSELD-ACLF) mortality was similar irrespective of presence or absence of COVID-19 infection. [...]it can be concluded that the severity of underlying liver disease is the ultimate killer rather than the COVID-19 infection. 1,4,7,9,10 Table 1 Outline of studies describing the outcome of COVID-19 infection in patients with cirrhosis Study details/year/author Nature of study Primary objective and outcomes Number of patients with cirrhosis Results of the study Index study (Sohail et al., 2023) 1 Retrospective record based cohort study from United States In patient mortality/MV/ICU stay and LOS 25 194 patients with cirrhosis and COVID-19 Patients with DC had higher mortality, longer hospital stay and higher hospitalization cost Sarin SK et al.